Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARS-1 (Intranasal Epinephrine) in Persistent Asthma
NCT05363670Phase 2Completed
- Sponsor
- ARS Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised trial of epinephrine nasal spray in asthma (2 arms), sponsored by ARS Pharmaceuticals. Primary endpoint: Effect of ARS-1 Versus Albuterol and Placebo at 1 hour. Started Jul 2022; status: completed.
02
Drugs
epinephrine nasal spray
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05363670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363670.